Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease
- PMID: 19686204
- DOI: 10.1111/j.1749-6632.2009.03885.x
Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease
Abstract
The presence of smell loss and the early pathological involvement of the olfactory pathways in the early stages of some neurodegenerative disorders are in accord with the tenants of the olfactory vector hypothesis. This hypothesis postulates that some such diseases may be caused or catalyzed by agents that enter the brain via the olfactory mucosa. In this study, rats infused intranasally (i.n.) with a low concentration of the proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) subsequently suffered olfactory, cognitive, and motor function impairments conceivably analogous to those observed during different stages of the development of Parkinson's disease (PD). Such infusion decreased the expression of the enzyme tyrosine hydroxylase in the olfactory bulb and substantia nigra by means of apoptotic mechanisms, reducing dopamine levels in different brain structures, such as the olfactory bulb, striatum, and prefrontal cortex. These findings reinforce the suggestion that the olfactory system may be a particularly sensitive route for the penetration of xenobiotic agents into the central nervous system and that the i.n. MPTP rat model may provide insight into the underlying mechanisms of PD pathogenesis, potentially leading to the development of new therapeutic strategies for this devastating disease.
Similar articles
-
The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.Exp Neurol. 2006 Dec;202(2):391-403. doi: 10.1016/j.expneurol.2006.07.001. Epub 2006 Aug 14. Exp Neurol. 2006. PMID: 16908021
-
Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.Behav Brain Res. 2012 Apr 1;229(1):208-15. doi: 10.1016/j.bbr.2012.01.016. Epub 2012 Jan 17. Behav Brain Res. 2012. PMID: 22266923
-
Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb.Life Sci. 2007 Apr 24;80(20):1906-14. doi: 10.1016/j.lfs.2007.02.021. Epub 2007 Feb 24. Life Sci. 2007. PMID: 17382353
-
The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.Curr Pharm Des. 2011;17(5):489-507. doi: 10.2174/138161211795164095. Curr Pharm Des. 2011. PMID: 21375482 Review.
-
[Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].Nihon Hoigaku Zasshi. 1998 Oct;52(5):301-5. Nihon Hoigaku Zasshi. 1998. PMID: 10077975 Review. Japanese.
Cited by
-
Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease.J Neural Transm (Vienna). 2011 Aug;118(8):1215-25. doi: 10.1007/s00702-010-0568-3. Epub 2011 Feb 8. J Neural Transm (Vienna). 2011. PMID: 21301897
-
Effects of L-arginine pre-treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's diseases in Balb/c mice.Iran J Neurol. 2015 Oct 7;14(4):195-203. Iran J Neurol. 2015. PMID: 26885338 Free PMC article.
-
Beneficial effects of L-arginine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuronal degeneration in substantia nigra of Balb/c mice.Adv Biomed Res. 2016 Aug 30;5:140. doi: 10.4103/2277-9175.187374. eCollection 2016. Adv Biomed Res. 2016. PMID: 27656609 Free PMC article.
-
A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.Brain. 2013 Feb;136(Pt 2):412-32. doi: 10.1093/brain/aws358. Brain. 2013. PMID: 23413261 Free PMC article.
-
Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.Neurotox Res. 2010 Feb;17(2):114-29. doi: 10.1007/s12640-009-9087-0. Epub 2009 Jul 21. Neurotox Res. 2010. PMID: 19629612
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical